Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Guangzhou MaxiNovel Awarded US Orphan Drug Status for AML Treatment

publication date: Mar 30, 2018

Guangzhou MaxiNovel Pharma has been granted Orphan Drug Designation in the US for MAX-40279, a proposed oral treatment for Acute Myeloid Leukemia (AML). According to MaxiNovel, clinical tests of MAX-40279 showed "potent" inhibition of both FLT3 and FGFR with excellent drug concentration in the bone marrow. MaxiNovel designed the molecule to overcome the drug resistance experienced by current FLT3 inhibitors due to bone marrow FGF/FGFR pathway activation. The company has filed to begin a Phase I trial of MAX-40279. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here